Expand ARVN Menu
ARVN MENU

ARVN Latest Press Releases

-- April 24, 2024 --

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer Globe Newswire 4:30 PM

-- April 11, 2024 --

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer Globe Newswire 7:00 AM

-- March 18, 2024 --

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer Globe Newswire 4:40 PM

-- March 4, 2024 --

Arvinas to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- February 27, 2024 --

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Globe Newswire 7:00 AM

-- February 20, 2024 --

Arvinas Announces Chief Financial Officer Transition Globe Newswire 4:05 PM
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC Protein Degrader for Neurodegenerative Disease Globe Newswire 7:00 AM

-- February 14, 2024 --

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer Globe Newswire 8:00 AM

-- February 6, 2024 --

Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer Globe Newswire 6:45 AM

-- February 1, 2024 --

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference Globe Newswire 4:30 PM

-- January 16, 2024 --

Arvinas Appoints Jared Freedberg as General Counsel Globe Newswire 5:01 PM

-- December 5, 2023 --

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program Globe Newswire 10:52 PM
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) and Plans to Expand Vepdegestrant Development Program Globe Newswire 1:33 PM

-- November 28, 2023 --

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium Globe Newswire 5:05 PM

-- November 27, 2023 --

Arvinas Announces Oversubscribed $350 Million Private Placement Globe Newswire 7:00 AM